- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT06910813
DFT383 em participantes pediátricos com cistinose nefropática (CYStem)
Um estudo de fase I/II de fase I/II de fase aberta e multicêntrico para avaliar a segurança, a tolerabilidade e a eficácia do DFT383 em participantes pediátricos com cistinose nefropática
An open-label, multi-center, phase I/II study to assess the safety, tolerability and efficacy of DFT383 in pediatric participants with nephropathic cystinosis, followed by a long-term extension phase.
The purpose of this clinical study is to assess safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis. The study consists of a Core Phase and a long-term Extension Phase. DFT383 is a cellular gene therapy.
This study includes an active arm (Cohort 1) of participants treated with study treatment DFT383 and a concurrent reference arm (Cohort 0). Participants in Cohort 0 will not receive study treatment and will only participate in the Core Phase of the study. The study is not randomized and Cohort 0 aims to collect prospective and concurrent data in this rare disease.
Visão geral do estudo
Descrição detalhada
This study is an open-label, multi-center, phase I/II study to assess the safety, tolerability, and efficacy of DFT383 in participants aged 2 to 5 years with nephropathic cystinosis, followed by a long-term extension phase.
The study includes two Treatment Groups (Cohort 1 and Cohort 0) and consists of a Core Phase and a long-term Extension Phase.
Participants in Cohort 1 will receive DFT383 and participate in both the Core and Extension Phase. Participants in Cohort 0 will not receive study treatment and will participate in the Core Phase only.
The two cohorts will be run in parallel. Investigational sites may participate in one or both cohorts.
Cohort 1 Approximately 15 participants will receive treatment with DFT383 in 3 (sub) cohorts (1A, 1B and 1C) dosed in a staggered approach. The total study duration for a participant in Cohort 1 will be up to 32 months in the core phase and up to 13 years for the long-term extension phase.
Cohort 0 Approximately 15 participants meeting similar inclusion/exclusion criteria and receiving SoC will be enrolled. The Schedule of Activities will be reduced for this Cohort. This cohort 0 is not a direct control but will provide essential context for interpreting the results observed in the participants receiving DFT383. The total study duration for a participant in Cohort 0 will be up to 24 months.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Novartis Pharmaceuticals
- Número de telefone: 1-888-669-6682
- E-mail: novartis.email@novartis.com
Estude backup de contato
- Nome: Novartis Pharmaceuticals
Locais de estudo
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85016
- Recrutamento
- Phoenix Children's Hospital (Recruiting Cohort 0 and 1)
-
Contato:
- Erica Sieber
- Número de telefone: 602-933-0171
- E-mail: esieber@phoenixchildrens.com
-
Investigador principal:
- Shanna White
-
-
California
-
San Diego, California, Estados Unidos, 92123
- Recrutamento
- University of California at San Diego - Rady Children's Hospital (Recruiting Cohort 0 and 1)
-
Contato:
- Mieko Pretlow
- Número de telefone: Ext 226010 858-966-1700
- E-mail: mpretlow@rchsd.org
-
Investigador principal:
- Nadine Benador nbenador@health.ucsd.edu
-
Stanford, California, Estados Unidos, 94305
- Recrutamento
- Stanford University - Stanford Children's Health (Recruiting Cohort 0 and 1)
-
Investigador principal:
- Alice Bertaina
-
Contato:
- Research Nurse
- Número de telefone: (650) 725-9032
- E-mail: scgt_clinical_trials_office@lists.stanford.edu
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Recrutamento
- Emory University School of Medicine - Children's Healthcare of Atlanta (recuiting Cohort 0)
-
Investigador principal:
- Laurence (Larry) Greenbaum
-
Contato:
- Laurence (Larry) Greenbaum
- Número de telefone: 404-712-6374
- E-mail: lgreen6@emory.edu
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Recrutamento
- Children's Hospital of Philadelphia (Recruiting Cohort 0)
-
Contato:
- Melissa Cadnapaphornchai
- Número de telefone: 215-590-2449
-
Investigador principal:
- Melissa Cadnapaphornchai
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Baylor College of Medicine - Texas Children's Hospital (recuiting Cohort 0)
-
Contato:
- Ewa Elenberg
- Número de telefone: 832-824-3800
- E-mail: Email_elenberg@bcm.edu
-
Investigador principal:
- Ewa Elenberg
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Key Inclusion Criteria:
Participants eligible for inclusion in this study must meet all the following criteria:
- Informed consent in writing from parent(s) or legal guardian(s) must be provided
- 2 to 5 years of age (including 5 years and 364 days old) at Screening
- Weight-for-stature is ≥ the third percentile, and is ≥ 10 kg
- Oral cysteamine therapy for at least 6 months
- Historic clinical diagnosis of nephropathic cystinosis
- Laboratory evidence of of renal fanconi syndrome (RFS)
- Relatively preserved kidney function (eGFR ≥ 60mL/min/1.73m2)
- Received all age-appropriate vaccinations
Key exclusion Criteria for Cohort 1 and 0
- A history of kidney transplantation
- A prior or planned bone marrow or stem cell transplantation or prior treatment with gene therapy
- History of malignancy
- A severe or uncontrolled medical disorder
- Major surgery within 90 days
Additional Key exclusion criteria for Cohort 1 - The following exclusion criterion applies to Cohort 1 only as it is related to DFT383 treatment:
1. Indomethacin within 2 weeks prior to Screening
Other protocol-defined inclusion/exclusion criteria may apply.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Cohort 1 (DFT383)
Treatment with DFT383 |
DFT383 is an autologous hematopoietic stem cell (HSC) gene therapy. |
|
Sem intervenção: Cohort 0 (SoC)
No study treatment, will continue with standard of care (cysteamine). |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Core Phase - Incidence of adverse events (Cohort 1)
Prazo: Up to 32 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 32 months
|
|
Core Phase - Number of participants with hematological reconstitution (Cohort 1)
Prazo: 42 days post DFT infusion
|
Hematological reconstitution by Day 42 post-DFT383 infusion |
42 days post DFT infusion
|
|
Core Phase - Proportion of participants with reversal of renal Fanconi syndrome (RFS)
Prazo: Up to 32 months
|
Proportion of participants with reversal of renal Fanconi syndrome (RFS) |
Up to 32 months
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Core Phase - Number of participants independent from cysteamine
Prazo: up to 24 months
|
Independence from oral and ophthalmic cysteamine |
up to 24 months
|
|
Core Phase - Health-related quality of life (HRQOL)
Prazo: Up to 32 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 32 months
|
|
Core Phase - Time from infusion to reversal of RFS (Cohort 1)
Prazo: Up to 24 months
|
Time from infusion to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Time from screening to reversal of RFS (Cohort 0)
Prazo: Up to 24 months
|
Time from screening to reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Duration of reversal of RFS
Prazo: Up to 24 months
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 24 months
|
|
Core Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR)
Prazo: Up to 27 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 27 months
|
|
Core Phase - Change from baseline on urine amino acids
Prazo: Up to 27 months
|
Change from baseline on urine amino acids |
Up to 27 months
|
|
Core Phase - Change from baseline on urinary glucose to creatinine ratio
Prazo: Up to 27 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR)
Prazo: Up to 27 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 27 months
|
|
Core Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr)
Prazo: Up to 27 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 27 months
|
|
Core Phase - Number of participants with improvement of proximal tubular function
Prazo: Up to 27 months
|
Improvement of proximal tubular function as defined by 2-fold change from Baseline of at least 4 out of 5 RFS parameters (urine protein to creatinine ratio, urine amino acids, urinary glucose to creatinine ratio, tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate, urine retinol-binding protein/creatinine ratio). Improvement will also be considered if the change from Baseline is less than 2-fold but the value falls within the definition for normalization. |
Up to 27 months
|
|
Core Phase - Corneal cystine crystal content
Prazo: Up to 27 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 27 months
|
|
Core Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Prazo: Up to 27 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 27 months
|
|
Core Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Prazo: Up to 27 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 27 months
|
|
Core Phase - Number of participants with malignancy (Cohort 1)
Prazo: Up to 27 months
|
Number of participants with malignancy |
Up to 27 months
|
|
Core Phase - Time to hematological reconstitution (Cohort 1)
Prazo: Up to 24 months
|
Time to hematological reconstitution |
Up to 24 months
|
|
Core Phase - Time to platelet engraftment (Cohort 1)
Prazo: Up to 24 months
|
Time to platelet engraftment |
Up to 24 months
|
|
Core Phase - Incidence of Adverse Events (Cohort 0)
Prazo: up to 24 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
up to 24 months
|
|
Extension Phase Primary Objective - Incidence of Adverse events (Cohort 1)
Prazo: Up to 15 years and 8 months
|
Number and proportion of participants with adverse events (AEs) and serious adverse events (SAEs) |
Up to 15 years and 8 months
|
|
Extension Phase - Number of participants with malignancy (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Number of participants with malignancy |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with presence/emergence of replication-competent lentivirus (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Number of participants with presence/emergence of replication-competent lentivirus |
Up to 15 years and 3 months
|
|
Extension Phase - Number of participants with clinically significant changes in vital signs, physical examinations, laboratories, and ECG (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Vital signs, physical examinations, laboratories (eg., chemistry, hematology, liver function tests), and ECG |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine protein to creatinine ratio (UPr/CR) (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Change from baseline on urine protein to creatinine ratio (UPr/CR) |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine amino acids (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Change from baseline on urine amino acids |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urinary glucose to creatinine ratio (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Change from baseline on urinary glucose to creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio (TmP/GFR) (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Change from baseline on tubular maximum reabsorption of Phosphate/Glomerular Filtration Rate ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Change from baseline on urine retinol-binding protein/creatinine ratio (RBP/Cr) (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Change from baseline on urine retinol-binding protein/creatinine ratio |
Up to 15 years and 3 months
|
|
Extension Phase - Duration of reversal of RFS (Cohort 1)
Prazo: Up to 15 years
|
Duration of reversal of renal Fanconi syndrome (RFS) |
Up to 15 years
|
|
Extension Phase - Number of participants with kidney failure (Cohort 1)
Prazo: Up to 15 years
|
Number of participants with kidney failure |
Up to 15 years
|
|
Extension Phase - Number of participants independent from cysteamine (Cohort 1)
Prazo: Up to 15 years
|
Independence from oral and ophthalmic cysteamine |
Up to 15 years
|
|
Extension Phase - Corneal cystine crystal content (Cohort 1)
Prazo: Up to 15 years and 3 months
|
Corneal crystal content by anterior segment optical coherence tomography (AS-OCT) |
Up to 15 years and 3 months
|
|
Extension Phase - Health-related quality of life (HRQOL) (Cohort 1)
Prazo: Up to 15 years and 8 months
|
Health-related quality of life (HRQOL) as measured by QUALIFY (cystinosis-specific PRO)- Currently under development |
Up to 15 years and 8 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Urogenitais Masculinas
- Doenças renais
- Doenças Urológicas
- Doenças Urogenitais Femininas
- Doenças urogenitais femininas e complicações na gravidez
- Metabolismo, Erros Inatos
- Doenças Genéticas, Congênitas
- Doenças Metabólicas
- Transporte Tubular Renal, Erros Inatos
- Doenças e Anormalidades Congênitas, Hereditárias e Neonatais
- Doenças Nutricionais e Metabólicas
- Cistinose
- Síndrome de Fanconi
- Doenças de Armazenamento Lisossomal
Outros números de identificação do estudo
- CDFT383A12101
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .